MYECO GROUP LTD — Capital/Financing Update 2015

May 14, 2015

==> picture [133 x 61] intentionally omitted <==

TO: COMPANY ANNOUNCEMENTS OFFICE

ASX LIMITED DATE: 15 May 2015

RIGHTS ISSUE

Further to SECOS Group Limited’s ( Company ) (ASX: SES) announcement on 8 May 2015, the Company is pleased to announce a rights issue to shareholders at $0.14 to raise $2,390,921 ( Rights Issue ). The Rights Issue will give existing eligible shareholders the opportunity to acquire 1 new share for every 6 existing shares held at 7.00pm on Thursday, 21 May 2015 ( Record Date ). Eligible shareholders are those shareholders at the Record Date with a registered address in Australia, New Zealand, or a shareholder that the Company has otherwise determined is eligible to participate.

The Rights Issue is non-renounceable, which means that shareholders may not transfer their shares if they do not wish to take them up.

The Rights Issue will have a top-up facility which may allow shareholders to apply for shares in excess of their entitlements. The Company also reserves the right to make a placement for any shortfall under the Rights Issue.

New shares issued under the Rights Issue will rank equally with existing ordinary shares on issue.

The indicative timetable for the Rights Issue is set out below:

Date*	Event
Friday, 8 May 2015	Announcement of the Placement
Wednesday,13 May 2015	Issue of Shares under Placement Cleansing Notice in respect of Placement and Appendix 3B lodged with ASX
Friday, 15 May 2015	Announcement of the Rights Issue
	Cleansing Notice in respect of Rights Issue, Information Booklet and Appendix 3B lodged with ASX
Tuesday, 19 May 2015	Ex-date commences
Thursday, 21 May 2015	Record Date for Rights Issue (7:00pm AEST)
Friday, 22 May 2015	Dispatch of Information Booklet and Entitlement and Acceptance Form to Eligible Shareholders
	Rights Issue opens
Friday, 19 June 2015	Rights Issue closes (5:00pm AEST)
Monday, 22 June 2015	Quotation on a deferred settlement basis

1

==> picture [133 x 61] intentionally omitted <==

Date*	Event
Tuesday, 23 June 2015	The Company notifies ASX of under-subscriptions
Friday, 26 June 2015	Issue date – Deferred settlement trading ends
	Dispatch of holding statements
Monday, 29 June 2015	New Shares expected to commence trading on the ASX

Further details of the Rights Issue are included in the Information Booklet released to ASX today.

Richard Tegoni Chairman SECOS Group Limited

2

==> picture [134 x 61] intentionally omitted <==

SECOS GROUP LIMITED

(ACN 064 755 237)

INFORMATION BOOKLET

1 for 6 Non-Renounceable Rights Issue at an Issue Price of $0.14 per New Share

Rights Issue closes: 5.00pm (AEST) on 19 June 2015

Lead Manager: Patersons Securities Limited

If you are an Eligible Shareholder, this is an important document that requires your immediate attention. It should be read in its entirety. You should consult your stockbroker, solicitor, accountant or other professional adviser if you have any questions.

1

==> picture [134 x 61] intentionally omitted <==

IMPORTANT NOTICES

This Information Booklet is dated 15 May 2015.

The Rights Issue is made in accordance with section 708AA of the Corporations Act. This Information Booklet does not contain all of the information which an investor may require to make an informed investment decision. This information in this Information Booklet does not constitute financial product advice and does not take into account your investment objectives, financial situation or particular needs.

This Information Booklet should be read in its entirety before you decide to participate in the Rights Issue.

By returning an Entitlement and Acceptance Form or otherwise paying for your New Shares or Top Up Shares though BPAY® in accordance with the instructions on the Entitlement and Acceptance Form, you acknowledge that you have read this Information Booklet and you have acted in accordance with and agree to the terms of the Rights Issue detailed in this Information Booklet.

No overseas offering

This Information Booklet and accompanying Entitlement and Acceptance Form do not constitute an offer or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer or invitation. In particular, this Information Booklet does not constitute an offer to Ineligible Shareholders. No action has been taken to lodge this Information Booklet in any jurisdiction outside of Australia, or to otherwise permit a public offering of Rights or Shares, in any jurisdiction outside Australia or New Zealand.

This Information Booklet is not to be distributed in, an no offer of New Shares or Top Up Shares is to be made in countries other than Australia, New Zealand and such other jurisdictions (and to such other Shareholders) that the Company determines are eligible to participate in the Rights Issue.

No action has been taken to register or qualify the Rights Issue, the Rights or the New Shares, or otherwise permit the public offering of the New Shares, in any jurisdiction other than Australia and New Zealand.

This distribution of this Information Booklet (including an electronic copy) outside Australia and New Zealand is restricted by law. If you come into possession of the information in this booklet, you should observe such restrictions and should seek your own advice on such restrictions. Any non-compliance with these restriction may contravene applicable securities laws.

Foreign exchange control restrictions or restrictions on remitting funds from your country to Australia may apply. Your Application for New Shares is subject to all requisite authorities and clearances being obtained for the Company to lawfully receive your Application Moneys.

New Zealand

The New Shares are not being offered to the public within New Zealand other than to existing Shareholders with registered addresses in New Zealand to whom the offer of New Shares is being made in reliance on the Securities Act (Overseas Companies) Exemption Notice 2013 (New Zealand).

This document has not been registered, filed with or approved by a New Zealand regulatory authority under the Securities Act 1978 (New Zealand). This document is not an investment statement or prospectus under New Zealand law and is not required to, and may not, contain all the information that an investment statement or prospectus under New Zealand law is required to contain.

Definitions, currency and time

Defined terms used in this Information Booklet are contained in Section 6. All references to time are to AEST, unless otherwise indicated. The Issue Price under the Offer is expressed in Australia dollars.

Taxation

There will be tax implications associated with participating in the Rights Issue and receiving New Shares. The Company recommends that you consult your professional tax advisor in connection with the Rights Issue.

Privacy

The Company collects information about each Applicant provided on an Entitlement and Acceptance Form for the purposes of processing the Application and, if the Application is successful, to administer the Applicant’s shareholding in the Company.

By submitting an Entitlement and Acceptance Form, you will be providing personal information to the Company (directly or through the Share Registry). The Company collects, holds and will use that information to assess your Application. The Company collects your personal information to process and administer your shareholding in the Company and to provide related services to you. The Company may disclose your personal information for purposes related to your shareholding in the Company, including to the Share Registry. The Company’s related bodies corporate, agents, contractors and third party service providers, including mailing houses and professional advisers, and to ASX and regulatory bodies. You can obtain access to personal information that the Company holds about you. To make a request for access to your personal information held by (or on behalf of) the Company, please contact the Company through the Share Registry.

2

==> picture [134 x 61] intentionally omitted <==

Governing law

This Information Booklet, the Rights Issue and the contracts formed on acceptance of the Applications are governed by the laws of Victoria, Australia. Each Applicant submits to the non-exclusive jurisdiction of the courts of Victoria, Australia.

No representations

No person is authorised to give any information or to make any representation in connection with the Rights Issue which is not contained in this Information Booklet. Any information or representation in connection with the Rights Issue not contained in the Information Booklet may not be relied upon as having been authorised by the Company or any of its officers. The Lead Manager has not authorised, permitted or caused the issue of this Information Booklet.

Future performance

This Information Booklet contains certain forward-looking statements with respect to the financial condition, results of operations, projects and business of the Company and certain plans and objectives of the management of the Company. These forward-looking statements involve known and unknown risks, uncertainties and other factors which are subject to change without notice.

Forward-looking statements are provided as a general guide only and there can be no assurance that actual outcomes will not differ materially from these statements. Neither the Company, nor any other person, gives any representation, warranty, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statement will actually occur. In particular, such forward-looking statements are subject to significant uncertainties and contingencies, many of which are outside the control of the Company.

US disclaimer

None of the information in this Information Booklet or the accompanying Entitlement and Acceptance Form constitutes an offer to sell, or the solicitation of an offer to buy, any securities in the USA. Neither this Information Booklet (or any part of it), the accompanying ASX announcement nor the accompanying Entitlement and Acceptance Form may be released or distributed directly or indirectly, to persons in the USA that are not Eligible Shareholders.

The New Share (and Top Up Shares) have not been, or will not be, registered under the US Securities Act or the securities laws of any state or other jurisdiction of the USA. The Rights under the Rights Issue may not be taken up by persons in the USA or by nominees or custodians who are acting for the account or benefit of a US person, and the New Shares (and Top Up Shares) may not be offered, sold or resold in the USA or to, or for the account or benefit of, a person in the USA except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable securities laws of any state or other jurisdiction in the USA.

3

Chairman’s Letter

==> picture [134 x 61] intentionally omitted <==

15 May 2015

Dear Shareholder

NON-RENOUNCEABLE RIGHTS ISSUE

I am pleased to invite you to participate in the Company’s continued growth through a non-renounceable rights issue to raise $2.4 million which offers Eligible Shareholders 1 fully paid ordinary share for every 6 Shares already held, at an issue price of $0.14 per share ( Rights Issue ). Shareholders who have applied to take up all their Rights to New Shares may also apply for Top Up Shares at the Issue Price. The Rights Issue is non-renounceable and only Shareholders on the Company’s register as of the Record Date will qualify to participate. The proceeds of the Rights Issue will be used to fund working capital requirements of the Company as included in Section 3.3 and in particular to support the Company’s growing order book. Patersons Securities Limited will act as lead manager in respect of the Rights Issue.

We are delighted with the response and feedback from investors on the newly merged entity. The Company announced on 8 May 2015 that it has successfully completed a private placement to professional and sophisticated investors ( Placement ) of 7,827,144 shares at an issue price of $0.14 per share, raising $1.1 million. The Rights Issue represents the first opportunity for existing Shareholders to invest in the new Company at the same price with the option to apply for Top Up Shares.

The two companies came together with a long list of synergies with the most compelling being the ability to produce Biohybrid™ cast films from Cardia Bioplastics Limited’s renewable resource based resins on Stellar’s large scale cast film production lines. These environmentally friendly, low carbon footprint, high quality and cost-competitive films are tailored for the global personal care, hygiene products, pet care and medical packaging industries. Based on their attractive performance, price and environmental profile the films have already attracted the attention of leading manufacturers of hygiene products around the world.

The immediate opportunity is to expand core sales with the use of spare capacity at the Company’s Deer Park, Australia manufacturing plant and then to grow market share with our trademarked Biohybrid™hygiene films together with the expansion of the Company’s organic waste diversion program. Funding from the Rights Issue represents a critical factor in delivering on the new Company’s strategy and we would like to thank our Shareholders for your continued support.

Yours faithfully

Richard Tegoni Chairman SECOS Group Limited

4

==> picture [134 x 61] intentionally omitted <==

Summary of Capital Raising

A summary of the key information in respect of the Placement and Rights Issue is shown in the table below. Shareholders should read this Information Booklet in its entirety before deciding to participate in the Rights Issue.

Placement as at 8 May 2015
Issue price	$0.14
Number of Shares	7,827,144
Gross proceeds	$1,095,800
Rights Issue
Ratio	1 New Share for every 6 existing ordinary Shares
Issue Price	$0.14
Number of New Shares	17,073,008
Gross proceeds	$2,390,221
Total gross proceeds	$3,486,021

Key Dates

Key dates in respect of the Placement and Rights Issue are set out in the table below.

Date*	Event
Friday, 8 May 2015	Announcement of the Placement
Wednesday,13 May 2015	Issue of Shares under Placement Cleansing Notice in respect of Placement and Appendix 3B lodged with ASX
Friday, 15 May 2015	Announcement of the Rights Issue
	Cleansing Notice in respect of Rights Issue, Information Booklet and Appendix 3B lodged with ASX
Tuesday, 19 May 2015	Ex-date commences
Thursday, 21 May 2015	Record Date for Rights Issue (7:00pm AEST)
Friday, 22 May 2015	Dispatch of Information Booklet and Entitlement and Acceptance Form to Eligible Shareholders
	Rights Issue opens
Friday, 19 June 2015	Rights Issue closes (5:00pm AEST)
Monday, 22 June 2015	Quotation on a deferred settlement basis
Tuesday, 23 June 2015	The Company notifies ASX of under-subscriptions
Friday, 26 June 2015	Issue date – Deferred settlement trading ends

5

==> picture [134 x 61] intentionally omitted <==

Date*	Event
	Dispatch of holding statements
Monday, 29 June 2015	New Shares expected to commence trading on the ASX

*This Timetable is indicative only. Applicants are encouraged to submit their Entitlement and Acceptance Form and Application Monies as soon as possible after the Rights Issue opens. The Directors may vary these dates, in consultation with the Lead Manager, subject to the Listing Rules. An extension of the Closing Date will delay the anticipated date for allotment and issue of the New Shares.

The Directors also reserve the right not to proceed with the whole or part of the Rights Issue any time prior to allotment and issue of the New Shares. In that event, the relevant Application Monies (without interest) will be refunded in full to Applicants.

Enquiries

If you are in any doubt as to the course you should follow, you should consult your stockbroker, accountant, solicitor or other professional adviser.

If you have questions on how to complete the Entitlement and Acceptance Form or take up your Rights, you should contact the Company Secretary on +61 3 9562 0122 at any time from 9:00am to 5:00pm AEST Monday to Friday before the Rights Issue closes.

If you have lost your Entitlement and Acceptance Form and would like a replacement form, you should contact the Share Registry.

1. Description of the Rights Issue

1.1 Overview of the Rights Issue

The Rights Issue is an offer of up to 17,073,008 shares at $0.14 per Share to raise up to $2,390,221.

Funds raised from the Rights Issue and the Placement will be used to fund working capital requirements of the Company as follows:

Intended use	Amount
Working capital to purchase raw materials to deliver business growth	$1.5 million
Technology development and patent cost	$0.3 million
Operating expenses	$0.73 million
Capital expenditure for expansion of film extrusion and bag making	$0.7 million
Estimated Expenses of the Placement and Rights Issue	0.27million
Total	$3.5 million

Eligible Shareholders who are on the Company’s share register on the Record Date are entitled to acquire 1 New Share for every 6 Shares held on the Record Date, at an issue price of $0.14 per New Share, which represents a discount of 16% to the closing price of $0.1668 over the last 5 trading days before the announcement of the Rights Issue. Fractional Rights will be rounded up to the nearest whole number of New Shares and holdings on different registers or sub-registers will not be aggregated to calculate entitlements.

An Entitlement and Acceptance Form setting out your Rights to New Shares accompanies this Information Booklet. If you have more than one holding of Existing Shares, you will be sent more than one personalised Entitlement and Acceptance Form and you will have a separate entitlement for each holding. Eligible Shareholders may subscribe for all or part of their Rights to New Shares. If an Entitlement and Acceptance Form does not accompany this Information Booklet, please contact the Company’s Share Registry.

The Rights Issue is non-renounceable. This means that Eligible Shareholders may not transfer their Rights if they do not want to take them up. Eligible Shareholders who choose to not take up their Rights will receive no benefit and their interest in the Company will be diluted.

6

==> picture [134 x 61] intentionally omitted <==

Eligible Shareholders may also apply for additional shares over and above their Rights under the Top Up Facility, although there is no guarantee they will receive the amount of Top Up Shares applied for, if any. There is no cap on the number of additional shares Eligible Shareholders may apply for, although the Top Up Share pool will be limited to the number of New Shares that relate to the Rights that have not been accepted under the Rights Issue.

The Directors reserve the right to allot and issue shares under the Top Up Facility at their discretion (in consultation with the Lead Manager).

The Rights Issue has no minimum subscription amount.

Eligible Shareholders should be aware that an investment in the Company involves risks. The key risks identified by the Company are set out in Section 4.

1.2

Placement

Under the Placement, the Company has issued up to 7,827,144 Shares to institutional and sophisticated investors at a price of $0.14 per Share. The Placement will raise $1,095,800.

Investors who receive Shares under the Placement will have those Shares registered by the Record Date and will be entitled to participate in the Rights Issue as Eligible Shareholders.

1.3 Lead Manager

Patersons Securities Limited will act as lead manager in respect of the Placement and the Rights Issue.

The Company and the Lead Manager have entered into a mandate letter ( Mandate ). The terms of the Mandate are as customary with these types of arrangements:

• (a) pay the Lead Manager a placement fee of 6% on the amount raised under the Rights Issue and the Placement, being $209,161 plus GST;

• (b) pay a corporate advisory fee of $60,000 (exclusive of GST); and

• (c) in the event that the Company or the Lead Manager terminates the Agreement the Company must pay the Lead Manager a termination fee of $60,000.

In addition, the Company has agreed to pay all of the Lead Manager’s reasonable out of pocket expenses of and incidental to the Rights Issue (including legal expenses and professional fees).

The Mandate also contains a number of indemnities, representations and warranties from the Company to the Lead Manager that are considered standard for an agreement of this type.

1.4 Eligibility of Shareholders

The Rights Issue is being made to all Eligible Shareholders.

The New Shares and Rights have not been and will not be, registered under the US Securities Act or the securities laws of any state or other jurisdiction of the USA and may not be offered or sold in the USA, except in transactions exempt from, or not subject to, such registration.

1.5 Treatment of Ineligible Shareholders

The Rights Issue is not being extended to Ineligible Shareholders because of the small number of such Shareholders, the number and value of Shares that they hold and the cost of complying with the applicable regulations in jurisdictions outside Australia, New Zealand and any other jurisdictions determined by the Company.

1.6 Ranking of New Shares

The New Shares will be fully paid and rank equally with Existing Shares.

1.7 Fractional Entitlements

Fractional Rights will be rounded up to the nearest whole number of New Shares and holdings on different registers or subregisters will not be aggregated to calculate entitlements.

1.8 Allotment

The Company has applied for quotation of the New Shares on ASX. Allotment of the New Shares under the Rights Issue is expected to take place no more than 6 Business Days after the close of the Rights Issue. Application Monies will be held by the Company on trust for Applicants until the New Shares are allotted. No interest will be paid on Application Monies.

7

==> picture [134 x 61] intentionally omitted <==

Trading of New Shares will, subject to ASX approval, occur on or about the date specified in the Timetable.

It is the responsibility of Applicants to determine the number of New Shares allotted and issued to them prior to trading in the New Shares. The sale by an Applicant of New Shares prior to receiving their holding statement is at the Applicant’s own risk.

1.9 Information Availability

Eligible Shareholders can obtain a copy of this Information Booklet during the period of the Rights Issue by calling the Company on +61 3 9562 0122 at any time from 9:00am to 5:00pm (AEST) Monday to Friday. Persons who access the electronic version of this Information Booklet should ensure that they download and read the entire Information Booklet.

If you have any questions on how to complete the Entitlement and Acceptance Form or take up your entitlement, please contact the Company Secretary on +61 3 9562 0122 from 9:00am to 5:00pm (AEST) Monday to Friday during the Rights Issue period.

2. Investor Presentation

Please see our most recent Investor Presentation attached as Annexure A.

3. Financial effect of the Rights Issue

3.1 ASX Announcements

The Company is listed on the ASX and is subject to regular reporting and disclosure obligations under the Corporations Act and the Listing Rules. These obligations require the Company to notify the ASX of information about specific events and matters as they arise as well as the lodgement of yearly and half-yearly financial statements and audit or review reports. The announcements and financial reports of the Company are available for inspection at ASX and may be viewed on the ASX website at www.asx.com.au.

3.2

General Financial Information

The Company’s financial information is prepared in accordance with Australian Accounting Standards. The accounting policies upon which the pro forma information in this Section has been prepared are set out in the Company’s audited annual financial statements for the period ended 30 June 2014 which can be viewed on the ASX website at www.asx.com.au.

The financial information contained in this Section is presented in an abbreviated form and does not contain all the disclosures that are usually provided in an annual report prepared in accordance with the Corporations Act.

3.3 Use of Funds

Funds raised from the Rights Issue and the Placement will be used to fund working capital requirements of the Company as follows:

Intended use	Amount
Working capital to purchase raw materials to deliver business growth	$1.5 million
Technology development and patent cost	$0.3 million
Operating expenses	$0.73 million
Capital expenditure for expansion of film extrusion and bag making	$0.7 million
Estimated expenses of the Placement and Rights Issue	$0.27 million
Total	$3.5 million

• a) The table assumes that none of the existing optionholders exercise their options before the Record Date and participate in the Rights Issue.

b) Operating expenses include but are not limited employment costs, marketing and distribution costs, corporate administration and operating costs that may be applied to ASX and Share Registry fees, legal, tax and audit fees and insurance costs.

8

==> picture [134 x 61] intentionally omitted <==

• c) The table is a statement of the proposed application of the funds raised as at the date of this Information Booklet. As with any budget, intervening events and new circumstances have the potential to affect the Company’s decisions and the Company reserves the right to vary the way the funds are applied.

• d) Actual expenditure may differ significantly from the above estimates due to a number of factors including market conditions, the development of new opportunities and other factors (including the risk factors outlined in Section 4 of this Information Booklet).

Assuming the Rights Issue is not fully subscribed, no existing options are exercised prior to the Record Date and where the Company raises less than $2.4 million, the Company will prioritise its use of funds towards the same objectives but with a greater emphasis on pursuing immediate sales opportunities and general working capital requirements.

There is no minimum aggregate subscription under the Rights Issue and the issue is not underwritten. Subject to the amount received by the Company, it will continue to closely monitor its expenditures having regard to the above priorities.

Shareholders should note that depending on the amount raised under the Rights Issue, the Company may require further capital in the immediate future, which may result in the issue of further Shares or seeking external finance.

3.4

Capital Structure

The capital structure of the Company following the issue of New Shares, assuming the maximum number of New Shares are issued under the Rights Issue, will be as follows:*

Shares on issue on announcement of Placement and Rights Issue	94,610,903
Shares issued under the Placement	7,827,144
New Shares to be issued under the Rights Issue	17,073,008
Shares on issue after the Placement and Rights Issue	119,511,055

*Excludes options and share rights.

The Company has 2,212,855 listed options on issue. The exercise price of all options will be adjusted in accordance with the ASX Listing Rules following the Rights Issue, in accordance with their terms. The options do not carry an entitlement to participate in the Rights Issue.

3.5 Balance Sheet Information

	Post Capital Raising & Acquisition
Particulars	(Amount in “000$)
Current Assets
Cash and Cash Equivalents	5,027
Trade & Other Receivables	4,741
Inventories	2,329
Total	12,097
Non Current Assets
Deferred Tax Assets	491
Financial Assets	563
Property,Plant & Equipment	4,610
Loan- Akkron	667
Investment in Akkron	13
Intangible Assets -Goodwill	-
Goodwill on merger	4,847
Total	11,191

9

==> picture [134 x 61] intentionally omitted <==

Total Assets	23,288
Current Liabilities
Trade and Other payables	6,016
Bank Overdrafts	486
Bank Borrowings	1,532
Equipment Finance Liabilities	634
Short termprovisions	693
Total	9,361
Non Current Liabilities
Related Party Loans	430
Bills Payable	1,116
Equipment Finance Liabilities	29
Longtermprovisions	113
Total	1,688
Total Liabilities	11,049
Net Assets	12,239
Equity
Issued Capital	12,405
Cost of capital raising	-270
Reserves	3,859
Accumulated Losses	-3,793
Parent Entity Interest	12,201
Non ControllingInterest	38
Total Equity	12,239

The pro forma consolidated balance sheet set out above has been derived from the Cardia's audit reviewed financials as at 31 December 2014 and Stellar's consolidated accounts as at 31 December 2014 and has been prepared for illustrative purposes to show the impact of the following pro forma adjustments:

• a) gross proceeds of the Placement and Rights Issue of $3.5 million; and

• b) estimated expenses of the Placement and Rights Issue of $0.27 million.

Bank borrowings disclosed in the balance sheet relate to the operations of Stellar’s trading operations of Stellar Films Group Pty Ltd (in Australia) and Stellar Films (Malaysia) Sdn Bhd (in Malaysia).

Included in current liabilities are:

• a) bank overdraft facilities of $A486,000 utilised as working capital facilities for both the Australian and Malaysian businesses;

• b) working capital facilities of $A1,532,000 raised by the Malaysian business which, as part of recently completed normal annual review of facilities, were restructured as a term loan facility. Whilst the repayment terms of the term loan facility result in a significant component of the term loan facility not being repayable within the next 12 months, the Company’s external auditors have adopted the conservative approach of recommending the total facility be classified as a current

10

==> picture [134 x 61] intentionally omitted <==

liability in response to the Malaysian bank’s facility letter of offer including a “repayable on demand” clause. It is noted, however, that:

• the term loan’s facility letter of offer includes a specific repayment which extends beyond 12 months; and

• it is generally accepted banking practice in Malaysia for letters of offer to include a standard “repayable on demand” clause irrespective of the whether or not the letter of offer contains specific repayment terms.

Included in non-current Liabilities are bills payable of A$1,116,000 which primarily relate to the funding of the Stellar’s equity investment in Akronn Industries Sdn Bhd. Going forward, the Malaysian business’ component of this liability (amounting to A$529,800) will be treated as a current liability in the group’s consolidated accounts in line with the Company’s external auditors’ recommendation as detailed above. Please also refer to the Company’s announcement dated 2 April 2015 addressing the above matter and satisfaction of condition precedent to the merger.

In preparing the pro forma accounts no assumptions have been made other than above stated two adjustments that the Company will raise $3.23 million (after costs) from the Placement and Rights Issue, which will result in an increase in cash and cash equivalents (current asset) and corresponding increase in issued capital (equity) by the amount raised. The Company will apply the funds raised for the purposes disclosed in Section 3.3 of the Information Booklet.

However, the consolidated balance sheet as at 31 December 2014 has been prepared on the assumption that the merger between Cardia Bioplastics Ltd and Stellar occurred on 1 July 2014 and is based on numerous assumptions that may or may not reflect the actual financial position of the Company after the completion of the Rights Issue.

In addition, the consolidated pro forma balance sheet is presented in summary format and does not contain all disclosures required under the Corporations Act.

The pro forma balance sheet is not represented as being indicative of the Company’s views on its future financial position. The pro forma balance sheet is presented on the assumption, after adjusting for the impact of changes set out above, that the Placement and Rights Issue took place on 31 December 2014 and, except as stated in the pro forma adjustments, does not take account of the financial performance, cash flow or other movements in balance sheet items of the Company for the period from 31 December 2014 to the date of this Information Booklet.

4. Risks

4.1 Overview

Set out below are some of the important business risks relevant to an investment in the Company. In addition, the Company is exposed to risks relevant to many businesses, including increasing competition, information systems failure risk and protection of intellectual property. This Section is intended to be a concise summary of the key risks to the Company’s business, not an exhaustive list of all possible risks.

References to the Company in this Section includes its subsidiaries.

4.2 Risks associated with the Company

Reliance on foreign markets

Due to the Company’s reliance on the Asian market (in particular, Malaysia and China), it is exposed to potential disruption or volatility. For example, the Company is exposed to risks relating to labour practices, environmental matters, costs associated with enforcing contracts, changes to and uncertainty in the relevant legal and regulatory regime (including in relation to taxation and foreign investment and practices of government and regulatory authorities) and other issues in those markets.

Currency risk

Revenue and expenditures in overseas jurisdictions are subject to the risk of fluctuations in foreign exchange markets. Any payment obligations of the Company in foreign currencies may exceed the budgeted expenditure if there are adverse currency fluctuations against the Australian dollar. The Company has sought to reduce this risk by entering into certain foreign currency hedging agreements.

Bribery and corruption in respect of foreign operations

The Company may incur fines or penalties, damage to its reputation or suffer other adverse consequences if its Directors, officers, employees, consultants, agents, service providers or business partners violate, or are alleged to have violated, antibribery and corruption laws in any of the jurisdictions in which it operates.

The Company cannot guarantee that its internal policies and controls will be effective in each case to ensure that the Company is protected from reckless or criminal acts committed by its Directors, officers, employees, consultants, agents, service providers

11

==> picture [134 x 61] intentionally omitted <==

or business partners that would violate Australian laws or the laws of any other country in which the Company operates. Any such improper actions could subject the Company to civil or criminal investigations in Australia or overseas, lead to substantial civil or criminal monetary or non-monetary penalties against the Company and damage the Company’s reputation. Even the allegation or appearance of improper or illegal actions could damage the Company’s reputation and result in significant expenditures in investigating and responding to such actions and in turn have an adverse effect on the Company’s future financial performance and position.

Operating risks

The operations of the Company may be affected by various factors, including (without limitation) contractual disputes, disruptions, supply shortages and labour conditions where the Company provides services.

Regulatory changes

The Company and many of its product applications that are sold into end markets are regulated by various national and local regulations. Changes in those regulations could result in additional costs, seizures, confiscations, recall or fines, any of which could prevent the Company from development and distribution of its products.

Reliance on key personnel

The Company currently employs a number of key management personnel, and the Company’s future depends on retaining and attracting suitably qualified personnel. The loss of key personnel could adversely affect the Company and its activities. The Company’s success depends, in part, on its ability to identify, attract, motivate and retain suitably qualified management personnel. Competition for qualified staff is strong, and the inability to access and retain the services of a sufficient number of qualified staff could be disruptive to the Company’s development efforts or business development and could materially adversely affect its operating results.

The Company has, as far as legally possible, established contractual mechanisms through employment and consultancy contracts to limit the ability of key personnel to join a competitor or compete directly with the Company. Despite these measures, however, there is no guarantee that the Company will be able to attract and retain suitably qualified personnel.

Reliance on third parties

The Company may pursue a strategy that forms strategic business relationships with other organisations in relation to potential products and services. There can be no assurance that the Company will be able to attract such prospective organisations and to negotiate appropriate terms and conditions with these organisations or that any potential agreements with such organisations will be complied with.

External suppliers

The Company relies on a number of external suppliers for the provision of services and feedstocks. There can be no assurance given that the failure of an external supplier(s) will not adversely affect the business of the Company.

Competition

The bioplastics and hygiene films market is competitive, and include companies with greater financial, technical, human, research and development and marketing resources than the Company. As a result, the Company’s current and future technologies and products may become obsolete or uncompetitive, resulting in adverse effects on revenue, margins and profitability.

Additional capital

The Company’s ability to continue its current operations and effectively implement future business plans may depend on its ability to raise additional funds. There is no guarantee that equity or debt funding will be available to the Company on favourable terms or at all, or that, when an existing facility expires or is otherwise terminated (for example, due to an event of default), the Company will be able to refinance that debt facility on reasonable terms.

An inability to raise additional funds or refinance existing facilities may have a material adverse effect on the Company’s operating and financial performance. If additional funds should be raised by issuing equity securities, this might result in dilution to the then existing shareholders.

Forecasts

The Directors consider that it is not possible to accurately predict the future revenues or profitability of the Company’s business or whether any revenues or profitability will eventuate. The business of the Company is dependent upon a number of factors and many of these factors are outside the control of the Company. Consequently the Company and the Directors do not make any forecast or representation in relation to the Company’s future financial position or performance.

12

==> picture [134 x 61] intentionally omitted <==

Unforeseen expenditure

The Company may need to incur unforeseen expenditure. Although the Company is not currently aware of any additional expenditure required, if such expenditure is subsequently incurred, this may adversely affect the expenditure proposals of the Company.

Litigation risk

Legal proceedings may arise from time to time in the course of the Company’s business and the Company cannot preclude the possibility that litigation may be brought against it, or that the Company may be impelled to initiate litigation against other parties in order to protect its legal rights. Litigation involves considerable cost, uncertain outcomes and possibly adverse publicity which negatively impact on the trading price and liquidity of Shares.

Force majeure

Force Majeure describes events including acts of God, fire, flood, earthquakes, war and strikes beyond the control of a party claiming the occurrence of any such event. To the extent that a Force Majeure event occurs, it may have a detrimental effect on the ability of the Company to operate, its financial performance and the value and price of Shares.

Environmental risk

The Company’s business model is based on the development and manufacture of environmental products. The Company may be subject to the market’s appetite and uptake of environmental products and other unforeseen events, such as changes in methodology and regulations, which may have adverse financial implications on the Company’s business model.

Limited operating history

The Company has only been operating as a merged entity since 7 April 2015. The Company may experience operational interruptions and integration issues resulting from the merger. In many respects, the merger has created a new company and therefore, the Company is subject to all of the risks inherent in a new business enterprise. Additionally, with a limited operating history as merged entity, it makes it difficult to evaluate the Company’s financial performance and prospects. As such, period to period comparisons of results from operations may not be meaningful.

Commercial success depends on widespread market acceptance of bioplastics

The market for bioplastics is a relatively young industry and is still developing. The Company’s success is dependent on consumers’ acceptance of these plastic products as well as the successful commercialisation of its plastics produced with the Company’s resins by third parties.

Ability to recycle existing plastics improves

Established product manufacturers could improve their ability to recycle their existing products or develop new environmentally friendly products which could render the Company’s technology less competitive. Any improvements or increased recycling of plastic products could lessen its harmful environmental impact, and have an adverse effect on the Company’s business.

Loss of key customers

There is no guarantee that the Company will be able to retain existing customers, or attract new customers in the future. This would materially adversely impact the Company’s operating results and viability.

Volatility of petroleum prices

The traditional plastics market is subject to fluctuations in petroleum prices. This hydrocarbon is a critical raw material in the development and manufacturing of plastics. Recently, these prices have been volatile and moved increasingly toward conditions that are supportive of the bioplastics market. With the bioplastic market currently commanding a premium price, any fall in petroleum prices could render bioplastics less competitive as the gap between bioplastic and traditional plastic pricing narrows.

Intellectual property protection

Commercial success may depend on the Company’s ability to obtain or maintain patents, trade secrets and trademark protection of its technology. Additionally, success may depend on the Company enforcing and defending its intellectual property against third-party challengers.

4.3 General risks

Market conditions

A number of factors affect the performance of share market investments that could also affect the price at which the Shares trade on the ASX. The market price of securities can fall as well as rise and may be subject to varied and unpredictable influences

13

==> picture [134 x 61] intentionally omitted <==

on the market for equities in general such as acts of terrorism, currency fluctuations and interest rate movements. These factors may materially affect the market price of the Shares regardless of the Company’s operational performance.

Economic risk

General economic conditions, introduction of tax reform, new legislation, movements in interest and inflation rates and currency exchange rates may have an adverse effect on the Company’s business activities and potential development programmes, as well as their ability to fund those activities.

Government factors

The introduction of new legislation or amendments to existing legislation by governments, and the decisions of courts and tribunals, can impact adversely on the assets, operations and, ultimately, the financial performance of the Company.

Any adverse developments in political and regulatory conditions in the countries in which the Company conducts business could materially affect the Company’s prospects. Political and environmental policy changes, such as changes in both monetary and fiscal policies, expropriation, methods and rates of taxation and currency exchange controls may impact the performance of the Company as a whole.

5. How to Apply

5.1

Shareholder Rights

The number of New Shares to which Eligible Shareholders are entitled (their Rights ) is shown on the accompanying Entitlement and Acceptance Form. Eligible Shareholders may:

• a) take up their Rights in full and, if they wish, apply for additional shares ( Top Up Shares ) under the Top Up Facility (refer to Section 5.2 and Section 5.3);

• b) take up part of the Rights (refer to Section 5.4); or

• c) allow all or part of the Rights to lapse (refer to Section 5.4).

Ineligible Shareholders may not take any of the steps set out in Sections 5.2 to 5.5.

The Company reserves the right to reject any Entitlement and Acceptance Form that is not correctly completed or that is received after the Closing Date. An Application for your Rights may be for any number of New Shares.

The Closing Date for acceptance of the Rights Issue is 5:00pm (AEST) on the Closing Date (however, that date may be varied by the Company in accordance with the Listing Rules.

5.2

Taking up all of your Rights

If you wish to take up your Rights in full, complete the Entitlement and Acceptance Form in accordance with the instructions set out on that form. If you have applied to take up all of your Rights to New Shares, you may also apply for Top Up Shares at the Issue Price by completing the relevant section on the Entitlement and Acceptance Form (see Section 5.4).

Please return your completed Entitlement and Acceptance Form together with your Application Monies in accordance with Section 5.6 for the amount shown on the Entitlement and Acceptance Form to the Share Registry so that it is received no later than 5:00pm (AEST) on the Closing Date .

You may also take up all of your Rights by arranging for payment of the Application Monies through BPAY® in accordance with the instructions on the Entitlement and Acceptance Form. If payment is being made through BPAY®, you do not need to return the Entitlement and Acceptance Form. Your payment must be received by no later than 5:00pm (AEST) on the Closing Date . You should be aware that your financial institution may implement earlier cut-off times with regards to electronic payment. You should take this into consideration when making payment.

5.3 Applying for Top Up Shares

Amounts received by the Company in excess of the Issue Price multiplied by your Rights ( Excess Amount ) may be treated as an application to apply for as many additional New Shares as your Excess Amount will pay for in full.

There is no guarantee you will receive the amount of Top Up Shares applied for, if any. The pool of Top Up Shares will be limited to the number of New Shares that relate to the Rights that have not been accepted under the Rights Issue.

If you apply for additional New Shares under the Top Up Facility and your application is successful (in whole or in part) you will be issued the New Shares on 26 June 2015. Top Up Shares will only be allocated to Eligible Shareholders if and to the extent

14

==> picture [134 x 61] intentionally omitted <==

that the Company determines. The Directors, in consultation with the Lead Manager, reserve their right to allot and issue New Shares under the Top Up Facility at their discretion, having regard to the circumstances as at the close of the Rights Issue. Any Scaleback of applications for Top Up Shares will be at the Company’s discretion and the Company’s decision on the number of New Shares to be allocated to Eligible Shareholders will be final.

Any Application Monies received for more than your final allocation of New Shares and Top Up Shares (only where the amount is $1.00 or greater) will be refunded as soon as practicable. The refund method will be at the discretion of the Company. No interest will be paid to Applicants on any Application Monies received or refunded.

No Top Up Shares will be issued to a Shareholder which will result in them increasing their voting power in the Company above 19.99%.

5.4 Taking up part of the Rights

If you wish to take up part of your Rights, complete the Entitlement and Acceptance Form for the number of New Shares you wish to take up and follow the other steps required in accordance with Section 5.2. You may arrange for payment through BPAY® in accordance with the instructions on the Entitlement and Acceptance Form. If payment is made and the Company receives an amount that is less than the Issue Price multiplied by your Rights ( Reduced Amount ), your payment may be treated as an application for as many New Shares as your Reduced Amount will pay for in full.

5.5

Rights not taken up

If you do not wish to accept any part of your Rights, do not take any further action and the Rights will lapse at 5:00pm (AEST) on the Closing Date .

If you do not accept your Rights in accordance with the instructions set out above, any New Shares that you would have otherwise been entitled to under the Rights Issue may be issued under the Top Up Facility. The number of Existing Shares you hold will not be affected if you choose not to accept any part of your Rights. However, Shareholders who do not participate in the Rights Issue will have their holdings diluted.

5.6

Payment

The consideration for the New Shares is payable in full on application by a payment of $0.14 per New Share. The Entitlement and Acceptance Form must be accompanied by a cheque for the Application Monies. Cheques must be drawn in Australian currency on an Australian bank and made payable to ‘ SECOS Group Limited – Share Subscription Account ’ and crossed ‘Not Negotiable’.

You should ensure that sufficient funds are held in relevant account(s) to cover the Application Monies. If the amount of your cheque for Application Monies (or the amount for which the cheque clears in time for allocation) is insufficient to pay for in full for the number of New Shares you have applied for in your personalised Entitlement and Acceptance Form, you will be taken to have applied for such lower number of whole New Shares as your cleared Application Monies will pay for (and to have specified that number of New Shares on your personalised Entitlement and Acceptance Form. Alternatively, your application may not be accepted. Please note that post-dated cheques may not be accepted.

Alternatively, you may arrange for payment of the Application Monies through BPAY® in accordance with the instructions on the Entitlement and Acceptance Form.

Please make sure to use the specific Biller Code and unique Reference Number on your personalised Entitlement and Acceptance Form. If you receive more than one personalised Entitlement and Acceptance Form, please only use the Reference Number specific to the Rights on that form. If you inadvertently use the same Reference Number for more than one of your entitlements, you will be deemed to have applied for Top Up Shares on the Entitlement and Acceptance Form to which that Reference Number applies to the extent the application exceeds the entitlement that relates to that Reference Number.

Eligible Shareholders must not forward cash by mail. Receipts for payment will not be issued.

5.7

Entitlement and Acceptance Form is binding

A completed and lodged Entitlement and Acceptance Form, or a payment made through BPAY® constitutes a binding offer to acquire New Shares on the terms and conditions set out in the Information Booklet and, once lodged or paid, cannot be withdrawn. If the Entitlement and Acceptance Form is not completed correctly it may still be treated as a valid application for New Shares. The Directors’ (or their delegates’) decision whether to treat an acceptance as valid and how to construe, amend or complete the Entitlement and Acceptance Form is final.

By completing and returning your personalised Entitlement and Acceptance Form with the requisite Application Monies or making a payment through BPAY®, you will also be deemed to have acknowledged, represented and warranted on behalf of each person on whose account you are acting that:

15

==> picture [134 x 61] intentionally omitted <==

• a) you are an Eligible Shareholder and are not in the USA and are not a nominee or custodian acting for the account or benefit of a person in the USA, unless the Company has given you notice that you are eligible to participate in the Rights Issue, and are not otherwise a person to whom it would be illegal to make an offer or issue of New Shares (or Top Up Shares) under the Rights Issue;

• b) you acknowledge that the New Shares (and Top Up Shares) have not been, and will not be, registered under the US Securities Act or under the laws of any other jurisdiction outside Australia or New Zealand; and

• c) you have not and will not send any materials relating to the Rights Issue to any person in the USA.

5.8 Shortfall

Shortfall Shares may arise if applications received for the New Shares (including after the completion of the Top Up Facility) are less than the number of New Shares offered.

The Company reserves the right to place Shortfall Shares at its discretion, in consultation with the Lead Manager and subject to the requirements of the Listing Rules and the Corporations Act, to place Shortfall Shares (if any) within 3 months after the Closing Date. The issue price of the Shortfall Shares will not be less than the Issue Price.

6. Definitions

$ means Australian dollars.

AEST means Australian Eastern Standard Time.

Applicant means an Eligible Shareholder who has applied to subscribe for New Shares by submitting an Entitlement and Acceptance Form or arranging for payment through BPAY® in accordance with instructions on the Entitlement and Acceptance Form.

Application means the submission of an Entitlement and Acceptance Form accompanied by the relevant Application Monies or arranging for payment of the relevant Application Monies through BPAY® in accordance with instructions on the Entitlement and Acceptance Form.

Application Monies means the aggregate amount payable for the New Shares applied for in a duly completed Entitlement and Acceptance Form or through BPAY®.

ASIC means the Australian Securities and Investments Commission.

ASX means ASX Limited (ACN 008 624 691) and the securities exchange operated by it (as applicable).

Board means the board of Directors of the Company.

Business Day has the same meaning as in the Listing Rules.

Closing Date means 5:00pm (AEST) 19 June 2015, the day the Rights Issue closes.

Company means SECOS Group Limited (ACN 064 755 237).

Corporations Act means the Corporations Act 2001 (Cth).

Director means a director of the Company.

Eligible Shareholder means a Shareholder on the Record Date who:

• a) has a registered address in Australia, New Zealand or a Shareholder that the Company has otherwise determined is eligible to participate;

• b) subject to a determination by the Company as outlined in (a), is not in the USA and is not a nominee or custodian acting for the account or benefit of a person in the USA; and

• c) is eligible under all applicable securities laws to receive an offer under the Rights Issue.

Entitlement and Acceptance Form means the Entitlement and Acceptance Form accompanying this Information Booklet.

Existing Shares means the Shares already on issue in the Company on the Record Date.

Ineligible Shareholder means a Shareholder (or beneficial holder of Shares) on the Record Date with a registered address outside Australia, New Zealand and any other jurisdiction that the Company determines and the Lead Manager agree to who ASX Listing Rule 7.7.1(a) applies.

16

==> picture [134 x 61] intentionally omitted <==

Information Booklet means this document.

Issue Price means $0.14 per New Share.

Lead Manager means Patersons Securities Limited.

Listing Rules means the official listing rules of ASX.

New Shares means Shares to be allotted and issued under the Rights Issue.

Placement means the placement of 7,827,144 Shares to institutional and sophisticated investors to raise $1,095,800, as announced on 8 May 2015.

Record Date means 7:00pm (AEST) on 21 May 2015.

Right means the right to subscribe for New Shares pursuant to the Rights Issue.

Rights Issue means the pro rata non-renounceable offer to Eligible Shareholders to subscribe for 1 New Share for every 6 Existing Shares at the Issue Price.

Scaleback means a reduction in the number of shares allotted to Eligible Shareholders who lodge an Application.

Section means a section of this Information Booklet.

Share means a fully paid ordinary share in the capital of the Company.

Share Registry means Advanced Share Registry Limited (ABN 14 127 175 946).

Shareholder means a holder of Shares.

Shortfall Shares means those New Shares not taken up by Eligible Shareholders under the Rights Issue.

Stellar means each of:

a) Stellar Films Group Pty Ltd (ACN 090 719 876); and

b) Stellar Films (Malaysia) Sdn Bhn (Company No: 266489-T).

Timetable means the indicative timetable set out on page 5 of the Information Booklet.

Top Up Facility means the facility described in Section 5.3under which Eligible Shareholders may apply for Top Up Shares in excess of their Rights.

Top Up Shares means New Shares available under the Top Up Facility.

US Person has the meaning given to that term in Regulation S under the US Securities Act.

US Securities Act means the US Securities Act of 1933 , as amended.

USA means the United States of America.

17

==> picture [134 x 61] intentionally omitted <==

7. Corporate information

Registered Office

SECOS Group Limited (ACN 064 755 237) Unit 18, 35 Dunlop Road Mulgrave VIC 3170 Telephone +61 3 9562 0122

Share Registry

Advanced Share Registry 110 Stirling Highway Nedlands WA 6009 Telephone +61 8 9389 8033

Lead Manager

Patersons Securities Limited 333 Collins Street Melbourne VIC 3000 Telephone +61 3 9242 4000

18

==> picture [134 x 61] intentionally omitted <==

Annexure A – Investor Presentation

19

==> picture [227 x 228] intentionally omitted <==

Investor Presentation 2015 Leading developer & manufacturer of sustainable packaging

==> picture [781 x 68] intentionally omitted <==

Disclaimer

Forward looking statements disclaimer

• "This presentation may contains “forward-looking statements.” Such forward-looking statements may include, without limitation:

• (i) estimates of future earnings;

• (ii) estimates of future production and sales;

• (ii) estimates of future cash costs;

• (iv) estimates of future cash flows;

• (v) statements regarding future debt repayments; and (vi) estimates of future capital expenditures.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. However, forward looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Such risks include, but are not limited to increased production costs, as well as political and operational risks in the countries and states in which we operate or sell product to, and governmental regulation and judicial outcomes.

The Company does not undertake any obligation to release publicly any revisions to any “forward-looking statement” to reflect events or circumstances after the date of this presentation, or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

All financial amounts are expressed in Australian dollars unless otherwise indicated."

==> picture [781 x 68] intentionally omitted <==

Cardia Bioplastics and Stellar Films Merger

Overview of Stellar and Cardia

Cardia Bioplastics Summary

Richard Tegoni Executive Chairman Frank Glatz Managing Director Steven Bendel Non-Executive Director Gideon Meltzer Non-Executive Director

Australian Securities Exchange (ASX: code)	SES
Shares on issue (ASX)	4,250m
Share price (average traded over last 90 days)	0.2 cents
Market capitalisation	$8.50m
Listed options on issue (ASX: CNNOB)
Exercisable at 1.5c any time to 30 June	221.3m
2015
Rolling monthly turnover	40m
Top 20 shareholders	45.3%
Total number of shareholders (as at 24 February 2015)	1,450

Stellar Films and Cardia Bioplastics Profiles

	Stellar Films	Cardia Bioplastics
Business	• Manufacturer and global marketer of high quality cast films • 50.8% ownership in Akronn producing silicone-coated film and paper products	• Global developer and manufacturer of bioplastic resins and finished products derived from renewable resources
Products	• Cast films and packaging, release liners	• Resins, films & packaging, waste management products, carrier bags
Target markets	• Personal care, hygiene, pet care and medical product markets	• Personal care, hygiene, pet care, protective packaging, councils, waste management, retail markets
Locations	• Headquartered in Melbourne • Manufacturing facilities in Melbourne, Port Klang and Nilai, Malaysia. • Sales offices: Melbourne, Port Klang • Global distributor network	• Headquartered in Melbourne • Manufacturing facilities in Nanjing, China • Sales offices in Melbourne, Nanjing, Kuala Lumpur, Vancouver, Sao Paulo • Global distributor network
Sales FY2014 Sales 1H2015	• $21.5 million • $10.6 million	• $5.0 million • $3.7 million

Merger Synopsis

• Consideration:

• Owners of Stellar Films Group will be issued an aggregate of 55% of the issued shares in Cardia on a postconsolidation basis in consideration for 100% of the issued shares and units in Stellar Films Group

• SECOS Group raising $3.5 million in equity via a share placement and rights issue

• Funds to be used for working capital, operating expenses and production expansion to deliver sales growth

Stellar Films Group value includes

• Stellar operations as going concern

• Manufacturing, sales and distribution

• Lease hold and facilities at Port Klang

• Plant, equipment and machinery in Deer Park, Australia and Port Klang, Malaysia

• 50.8% of Akronn business

• Stellar Films Group brand, logos & trademarks, intellectual property, customer contracts and know how

• Inventory ($ 1.8 million, Dec 2014)

• Debtors ($ 4.1 million, Dec 2014)

• Creditors ($ 5.9 million, Dec 2014)

==> picture [781 x 68] intentionally omitted <==

Merger Rationale

• Market access and reach in absorbent hygiene products market - $72 billion industry growing 5.5% per annum, and emerging, high growth Bioplastics industry with focus on packaging, waste management products and carrier bags target market segments.

• Unique global product offering to absorbent hygiene products market – environmentally preferred, made from renewable resources, lower carbon foot print, heavy metal free, silicone coated hygiene products.

• Enhanced competitiveness through integrated production from resins to films to coated products.

• Geographic footprint of combined operations. Focus on high growth Asian market.

• Stellar’s underutilised production assets. Production and supply chain efficiency. Operational savings. Cost effective expansion options.

• Complementary intellectual property positions and customer reach.

• Highly focused management teams with internationally recognised industry experts in sustainable packaging.

• Scale and resources to deliver the successful implementation of growth strategy in hygiene films and bioplastics products.

==> picture [781 x 68] intentionally omitted <==

SECOS Group Summary

==> picture [362 x 31] intentionally omitted <==

----- Start of picture text -----

Board of Directors
----- End of picture text -----

Richard Tegoni Non-executive Chairman Stephen Walters Group Managing Director Frank Glatz CEO Bioplastics Business Trevor Haines Chief Financial Officer Gideon Meltzer Non-Executive Director

==> picture [362 x 32] intentionally omitted <==

----- Start of picture text -----

Business
----- End of picture text -----

• Leading developer & manufacturer of sustainable packaging

• High quality cast films, bioplastic resins & finished products derived from renewable resources for the global packaging industry

==> picture [345 x 31] intentionally omitted <==

----- Start of picture text -----

Capital Structure after consolidation
----- End of picture text -----

	Australian Securities Exchange (ASX: code)	SES
	Shares on issue (ASX)	94.45 m
	Share price	20 cents
	Market capitalisation	$18.9m
	Listed options on issue (ASX:
	CNNOB) Exercisable at $1.5 any	2.2m
	time to 30 June 2015
	Top 20 shareholders	73%
	Total number of shareholders (as at 15 March 2015)	1,500

• Changing the world of packaging

==> picture [781 x 68] intentionally omitted <==

SECOS Group Overview

• ASX-listed company (ASX: SES) formed through merger of Cardia Bioplastics and Stellar Films.

• Corporate and operational centre in Melbourne, Australia.

• Manufacturing plants in Deer Park (Australia), Port Klang (Malaysia) and Nanjing (China).

• Akronn Joint Venture (50.8%) for silicone coated products in Nilai (Malaysia)

• Sales & operational offices in Australia, Malaysia, China, USA and Brazil.

• Established global distributor network across the Americas, Europe, Asia, Middle East and Africa.

==> picture [781 x 253] intentionally omitted <==

----- Start of picture text -----

Global Operations
Resin Production Finished Goods Sales Offices Distributors
----- End of picture text -----

Absorbent hygiene products market

• Absorbent hygiene products: baby diapers, feminine hygiene products and adult incontinence products

• $72 billion industry growing 5.5% a year.

• Growth across both developed & developing markets.

• Driven by demographics & economic development.

• Consumers demand more environmentally friendly, non-toxic hygiene products

• Tailwinds

• Births across Asia are rising

• Population of women expected to rise

• Aging population is growing

• Disposable income is increasing with middle class

• Headwinds - Sustainable growth requires environmental sustainability

• Transform our supply chain with renewable materials

• Eliminate manufacturing and operating waste

• Create industry-led solutions to post-consumer solid waste created by our products

==> picture [191 x 339] intentionally omitted <==

==> picture [781 x 68] intentionally omitted <==

Bioplastics Industry

• Bioplastics: bio-based and/or biodegradable plastics

• Increased “package goods” consumption due to continued economic development and societal trends towards convenience.

==> picture [185 x 130] intentionally omitted <==

• Growth of middle classes & increased consumerism in developing countries.

• Uncertainty around oil (price and future availability) as a key input in traditional plastics.

• Increased Government regulation of environmental issues and waste management: legislation and taxes.

• Organic waste diversion being implemented around the world.

• Increased costs of landfills (globally).

• Increased consumer demand for sustainable products due to awareness of environmental issues.

• Global brand leaders are investing in the transition from traditional plastics to bioplastics - tracking consumer preference trends and preparing for global legislative changes.

• Sustainable and renewable Bioplastics packaging is estimated to be < 1% of the plastics packaging market (c.$200B p.a.) with exponential growth potential.

==> picture [307 x 228] intentionally omitted <==

----- Start of picture text -----

Global Produc on Capacity of Bioplas cs
7000
6185
6000
5185
5000
4000
3000
2000
1395
1161
989 1000
1000 647 675 486 791 604
180 185 258 276 342
5 18
0
2006 2008 2010 2011 2012 2017 Forecast
Year
Compostable Bioplas cs Non Compostable Bioplas cs Total Capacity
1000 Metric Tons
----- End of picture text -----

Source: European Bioplastics/ IfBB Industry Report 2013

==> picture [781 x 68] intentionally omitted <==

SECOS Group Manufacturing Plants

==> picture [215 x 143] intentionally omitted <==

==> picture [215 x 144] intentionally omitted <==

==> picture [215 x 143] intentionally omitted <==

Resin production in Nanjing (China)

Film production in Nanjing (China)

Film production in Port Klang (Malaysia)

==> picture [215 x 144] intentionally omitted <==

==> picture [215 x 144] intentionally omitted <==

==> picture [215 x 144] intentionally omitted <==

Bag production in Nanjing (China)

Film coating in Nilai (Malaysia)

Film production in Deer Park (Australia)

==> picture [781 x 68] intentionally omitted <==

Manufacturing Plants & Volume Capabilities

SECOS Group has developed proprietary manufacturing processes for its bioplastic resin, cast films and finished products

• SECOS Group manufacturing plants are located in Deer Park (Australia), Port Klang (Malaysia) and Nanjing (China).

• SECOS Group specializes in production of its high quality cast films, bioplastic resins & finished products derived from renewable resources.

• It extends its product range through its Akronn Joint Venture (50.8%) for silicone coated products in Nilai (Malaysia)

==> picture [257 x 136] intentionally omitted <==

• Annual production capacity of c. 7,200 tonnes of bioplastics resins and c. 17,000 tonnes of film and finished products with cost effective capacity expansion options.

• SECOS Group has set up fully integrated product supply from bioplastic resin to certified compostable and Biohybrid™ films and bags that ensures product quality and cost competiveness.

• Quality systems ISO9001 certified.

==> picture [257 x 136] intentionally omitted <==

==> picture [781 x 68] intentionally omitted <==

SECOS Group Global Customers

SECOS Group delivered sales or is in commercialisation developments with the following leading global brands:

==> picture [149 x 29] intentionally omitted <==

==> picture [67 x 30] intentionally omitted <==

==> picture [137 x 49] intentionally omitted <==

==> picture [62 x 43] intentionally omitted <==

==> picture [109 x 57] intentionally omitted <==

==> picture [60 x 46] intentionally omitted <==

==> picture [57 x 58] intentionally omitted <==

==> picture [54 x 52] intentionally omitted <==

==> picture [101 x 52] intentionally omitted <==

==> picture [133 x 32] intentionally omitted <==

==> picture [117 x 44] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [109 x 44] intentionally omitted <==

==> picture [103 x 29] intentionally omitted <==

==> picture [84 x 43] intentionally omitted <==

==> picture [110 x 32] intentionally omitted <==

==> picture [134 x 44] intentionally omitted <==

==> picture [72 x 72] intentionally omitted <==

==> picture [124 x 32] intentionally omitted <==

==> picture [95 x 47] intentionally omitted <==

==> picture [74 x 46] intentionally omitted <==

==> picture [56 x 78] intentionally omitted <==

==> picture [83 x 46] intentionally omitted <==

==> picture [781 x 68] intentionally omitted <==

SECOS Group Product Offering

• High quality cast films for personal care, hygiene, pet care and medical product applications.

• Embossed barrier, laminated, multi-layer, printed or general packaging films.

• Paper or film release liners for the personal care, hygiene, photo voltaic and graphic arts industries.

• Standard plastic or sustainable film options with

• Tailored release properties for specific customer applications.

• Certified biodegradable & compostable

• Made with less oil

• Contain GMO free, renewable, plant based material

• Can be composted in aerobic composting plants

• Turned into compost, condition soil for improved plant growth, independently verified

• Made with less oil & heavy metal free

• Contain GMO free, renewable, plant based material

• Reduces global warming by sequestering CO2

• Lower carbon foot print verified by independent Life Cycle Assessment

• Cost effective alternative to fossil fuel derived films

SECOS Group Hygiene Films & Packaging

==> picture [189 x 126] intentionally omitted <==

==> picture [193 x 130] intentionally omitted <==

==> picture [200 x 127] intentionally omitted <==

==> picture [197 x 127] intentionally omitted <==

==> picture [146 x 130] intentionally omitted <==

==> picture [169 x 127] intentionally omitted <==

==> picture [155 x 139] intentionally omitted <==

==> picture [177 x 127] intentionally omitted <==

==> picture [781 x 89] intentionally omitted <==

Standard feminine hygiene product vs SECOS feminine hygiene product

PE pouch packaging Biohybrid™pouch packaging silicone coated

PE back sheet Biohybrid™back sheet Release papers No release paper

==> picture [300 x 201] intentionally omitted <==

==> picture [299 x 201] intentionally omitted <==

• Benefits: - No release paper (cost savings)

• Lower carbon foot print

• Made with less oil

• Matt finish, satin touch

• Heavy metal free

==> picture [781 x 68] intentionally omitted <==

Patents & International Accreditation

SECOS Group has developed and retains a strong Intellectual Property portfolio:

• 11 Patent families for bioplastic resins & packaging products. 20 patents so far granted in key markets.

• Patents protect composition formulation, manufacturing process and applications for global packaging products invented by The Group’s R&D team.

International Accreditation

• Accredited globally, in all countries with certification schemes – including the USA, EU, China, Australia, South America, Japan & Asia.

• Food contact approval in Europe and USA. Halal Certification.

• Nanjing plant certified to China Environmental Standard.

• The Group’s Malaysian business awarded BioNexus Status.

==> picture [63 x 74] intentionally omitted <==

==> picture [74 x 78] intentionally omitted <==

==> picture [77 x 77] intentionally omitted <==

==> picture [146 x 78] intentionally omitted <==

==> picture [65 x 59] intentionally omitted <==

==> picture [45 x 65] intentionally omitted <==

==> picture [781 x 68] intentionally omitted <==

SECOS Global Activities Group

Applications	ANZ		China	North America	North America	Brazil	Brazil	Europe/ Middle East	SE Asia (focus Malaysia)
Hygiene films & Packaging	✔✔✔		✔	✔✔✔		✔		✔✔✔	✔✔✔
Waste management products	✔✔✔		✔✔✔	✔✔✔		✔✔		✔✔	✔✔✔
Carrier Bags	✔		✔✔	✔		✔✔✔		✔	✔
		✔ ✔✔ ✔✔✔ Low Medium High
		✔			✔✔		✔✔✔
		Low			Medium		High

==> picture [781 x 68] intentionally omitted <==

Financial Summary – December 2014 Proforma

Profit & Loss - Half Year July – December 2014	Profit & Loss - Half Year July – December 2014	Profit & Loss - Half Year July – December 2014
	($000’s)	% of Revenue
Revenue	12,958	100%
Gross Margin	1,517	12%
Overheads	3,945	30%
Other income	509
Normalised EBITDA	(1,919)	(15%)
Adjustments	1,101
EBITDA after adjustments	(3,020)	(23%)

==> picture [781 x 68] intentionally omitted <==

Commentary on trading results

• Trading summary reflects:

• Consolidated results of both Cardia and Stellar for half year to December 2014.

• • Normalised trading with Brazil’s results removed from trading statement and disclosed as an adjustment to EBITDA.

• Abnormals arising from Stellar’s restructure of manufacturing operations.

• Gross margin reflects:

• Unfavourable exchange rate environment and high polymer prices.

• Stellar’s reduced production (arising from restructure) impacting margins.

• Akronn’s trading for the half year reflecting a “start up” phase.

• Cardia China commenced production in new facilities with new work force impacting margins.

==> picture [781 x 68] intentionally omitted <==

Key Risks

Company specific

General risks

• Integration risk

• General economic conditions

• Potential decline of Stellar’s film sales

• Product liability

• Research and development risks

• Business interruption; production or development delays

• Intellectual property risks

• Variability and risks of capital markets

• Foreign exchange

• Government legislation

• Bribery and Corruption in respect to foreign operations

• Competition

• Unforeseen capital expenditure

• Occupational health & safety

• Reliance on third parties and key personnel

• Operating risks

• Forecasts

==> picture [781 x 68] intentionally omitted <==

Growth Opportunities

Short term (1 year)	Medium term (1 - 3 years)	Long term (3+ years)
Utilise excess capacity of Cardia resin and Stellar cast film production	Expand customers and sales of Biohybrid™hygiene films	Centered on development and marketing of sustainable packaging
Expand Cardia film and bag production at Stellar Malaysia plant	Expand roll out of organic waste diversion, specific Councils targeted	Absorbent hygiene products industry fully adopting products made from renewable resources
Successful commercialisation of Biohybrid™hygiene films	Legislation and bans of standard retail carrier bags	Global roll out of organic waste diversion
Deliver business growth based on current sales development activities	Deliver business growth based on current sales pipeline	Bioplastics becomes the product choice

==> picture [781 x 68] intentionally omitted <==

* Revenue & Capacity Range

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 13] intentionally omitted <==

==> picture [631 x 9] intentionally omitted <==

• The Lower range data is based on anticipated sales from customers’ orders using present day prices and known costs of production.

• Upper range data assumes full production capacity at existing facilities and additional production from planned expenditure using funds from the proposed capital raising

• Revenue includes 50.8% of Akronn revenue

• Refer to disclaimer regarding forward looking statements

==> picture [781 x 68] intentionally omitted <==

SECOS Group Investment Summary

• Only ASX-listed stock focused on sustainable packaging.

• Market access and reach in absorbent hygiene products market - $72 billion industry growing 5.5% per annum, and emerging, high growth Bioplastics industry.

• Highly focused management team with internationally recognised industry experts in sustainable packaging.

• Strong IP and patent position on technology and comprehensive range of high performance sustainable packaging products.

• Sales to high profile brand owners, retailers, packaging companies and Councils.

• Joint development with leading consumer goods and global packaging companies.

• Established global operations and distributor network.

• Cost-effective manufacturing in Nanjing, KL and Melbourne, with low cost expansion options.

• Well positioned to globally expand sales and marketing with unique environmentally friendly hygiene products that meet customer demands.

==> picture [781 x 68] intentionally omitted <==